Active	Status	Sponsor type	Region	Phase	Filter
5 Active 9 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kreuter, Michael
IMPALA-2, NCT04544293 / 2020-001263-85: Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	Active, not recruiting	3	160	Europe, Canada, Japan, US, RoW	Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), Placebo	Savara Inc., Savara ApS,	Autoimmune Pulmonary Alveolar Proteinosis	11/23	11/24
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease	Recruiting	3	440	Europe, Japan, US, RoW	Belimumab, BENLYSTA, GSK1550188, Placebo	GlaxoSmithKline	Lung Diseases, Interstitial	10/28	12/28
NCT05130970 / 2021-003162-12: Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis	Completed	2	81	Europe, Canada, US, RoW	Garadacimab, Factor XIIa antagonist monoclonal antibody, CSL312, Placebo	CSL Behring	Idiopathic Pulmonary Fibrosis	01/24	01/24
I-FILE, NCT04304898: An International Patient-led Registry in Fibrotic Interstitial Lung Diseases Using eHealth Technology	Recruiting	N/A	700	Europe	Home spirometry	Erasmus Medical Center	Pulmonary Fibrosis	07/25	07/26
ILDnose, NCT04680832: Exhaled Breath Analysis Using eNose Technology as a Biomarker for Diagnosis and Disease Progression in Fibrotic ILD	Recruiting	N/A	600	Europe	Electronic nose, SpiroNose, eNose	Erasmus Medical Center	Pulmonary Fibrosis	12/25	12/26